Bristol Myers secures FDA label expansion for anemia drug Reblozyl
Bristol Myers Squibb has scored another win for its anemia drug Reblozyl, revealing Monday evening the FDA granted the drug its third indication.
The FDA approved the drug as a frontline treatment for adult anemia patients with lower-risk myelodysplastic syndromes (MDS) who may require red blood cell transfusions, and who also had not used erythropoiesis-stimulating agents, or ESAs.
The agency accepted an sNDA for the drug back in May, granting it priority review.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
